Edit
PR Newswire
19 Jun 2013
MILAN, June 19, 2013 /PRNewswire/ -- ... ... Newron's additional projects are primarily addressed towards highly promising treatments for rare diseases and are at various stages of preclinical and clinical development, including sNN0031 for Parkinson's disease, sarizotan for Rett's syndrome, sNN0029 for ALS, ralfinamide for specific pain indications, and NW-3509 as potential first add-on therapy for the treatment of schizophrenia ... ....(size: 10.2Kb)
Edit
noodls
17 Dec 2012
(Source. Newron Pharmaceuticals SpA) Newron closes acquisition of NeuroNova ... ("Newron", SIX ... Newron (SIX ... Newron's additional projects are primarily addressed towards highly promising rare diseases and are at various stages of preclinical and clinical development, including sarizotan for Rett's syndrome, ralfinamide for specific pain indications, and NW -3509 as potential first add-on therapy for the treatment of schizophrenia ... Media ... 1/2....(size: 7.0Kb)
Edit
Newron's Shareholders with an overwhelming majority vote in favour of NeuroNova acquisition (Newron Pharmaceuticals SpA)
noodls05 Dec 2012
Newron's Shareholders with an overwhelming majority vote in favour of. NeuroNova acquisition ... ("Newron", SIX ... Newron's additional projects are primarily addressed towards highly promising rare diseases and are at various stages of preclinical and clinical development, including sarizotan for Rett's syndrome, ralfinamide for specific pain indications, and NW-3509 as potential first add-on therapy for the treatment of schizophrenia ... Media....(size: 9.4Kb)
Edit
noodls
14 Nov 2012
Newron provides update on submission plans for safinamide ... and Meiji Seika Pharma Co. Ltd ... Newron (SIX ... and pain ... Newron's additional projects are primarily addressed towards highly promising rare diseases and are at various stages of preclinical and clinical development, including sarizotan for Rett's syndrome, ralfinamide for specific pain indications, and NW-3509 as potential first add-on therapy for the treatment of schizophrenia ... 2/3....(size: 11.1Kb)
Edit
noodls
09 Nov 2012
Newron publishes agenda for Shareholder's meeting ... ("Newron", SIX ... Items on the agenda will include.. 1 ... 2 ... 3 ... 1/2 ... Newron's additional projects are primarily addressed towards highly promising rare diseases and are at various stages of preclinical and clinical development, including sarizotane for Rett's syndrome, ralfinamide for specific pain indications, and NW -3509 as potential first add-on therapy for the treatment of schizophrenia....(size: 9.2Kb)
Edit
Newron to resubmit acquisition of Swedish neurogenesis company NeuroNova AB to its shareholders (Newron Pharmaceuticals SpA)
noodls31 Oct 2012
Newron to resubmit acquisition of Swedish neurogenesis company. NeuroNova AB to its shareholders ... 17, 2012) ... 1/3 ... Newron's additional projects are primarily addressed towards highly promising rare diseases and are at various stages of preclinical and clinical development, including sarizotane for Rett's syndrome, ralfinamide for specific pain indications, and NW-3509 as potential first add-on therapy for the treatment of schizophrenia....(size: 14.8Kb)
Edit
noodls
19 Sep 2012
(Source. Newron Pharmaceuticals SpA) Decisions of Newron's Shareholders' Meeting ... ("Newron", SWX ... Newron (SIX ... Newron's additional projects are primarily addressed towards highly promising rare diseases and are at various stages of preclinical and clinical development, including sarizotane for Rett's syndrome, ralfinamide for specific pain indications, and NW-3509 as potential first add-on therapy for the treatment of schizophrenia ... them....(size: 8.7Kb)
Edit
noodls
10 Sep 2012
Newron Pharmaceuticals reports half-year results 2012. Milan, Italy - 10 September, 2012 - Newron Pharmaceuticals S.p.A. ("Newron", SIX ... Half-Year 2012 Highlights ... Smooth take-over of global safinamide development program from Merck Serono ... 2013." ... 1/3 ... 0 ... development, including sarizotane for Rett's syndrome, ralfinamide for specific pain indications, and NW-3509 as potential first add-on therapy for the treatment of schizophrenia ... ....(size: 15.4Kb)
Edit
noodls
05 Sep 2012
Newron information meeting for shareholders in Zurich. Milan, Italy - 4 September, 2012 - Newron Pharmaceuticals S.p.A. ("Newron", SIX ... Rolf Stahel, Chairman of Newron, said ... The acquisition of NeuroNova, a privately-owned CNS R&D; company based in Sweden will provide Newron with. ... The event will take place. ... Newron (SIX ... 3509 for the treatment of schizophrenia, as well as pruvanserin and sarizotan for treatment of CNS diseases ... Media ... Italy ... ....(size: 9.7Kb)
Edit
noodls
21 Aug 2012
Newron publishes agenda for Shareholder's Meeting -. Board strongly encourages shareholders to vote. Milan, Italy - 21 August, 2012 - Newron Pharmaceuticals S.p.A. ("Newron", SIX ... CET in the company's registered offices in Bresso (MI), Via L. Ariosto, 21, Italy. Items on the agenda will include.. 1 ... 2 ... 8, of the Italian Civil Code. 3 ... 4 ... 3509 for the treatment of schizophrenia, as well as pruvanserin and sarizotan for treatment of CNS diseases ... ....(size: 11.8Kb)
Edit
noodls
21 Aug 2012
Newron publishes agenda for Shareholder's Meeting -. Board strongly encourages shareholders to vote. Milan, Italy - 21 August, 2012 - Newron Pharmaceuticals S.p.A. ("Newron", SIX ... CET in the company's registered offices in Bresso (MI), Via L. Ariosto, 21, Italy. Items on the agenda will include.. 1 ... 2 ... 8, of the Italian Civil Code. 3 ... 4 ... 3509 for the treatment of schizophrenia, as well as pruvanserin and sarizotan for treatment of CNS diseases ... ....(size: 11.8Kb)
Edit
PR Newswire
21 Oct 2011
. GENF, Schweiz, October 21, 2011 /PRNewswire/ --. Merck Serono, eine Sparte der Merck KGaA, Darmstadt, Deutschland, gab heute die Entscheidung bekannt, sämtliche Rechte an Safinamid an Newron Pharmaceuticals S.p.A. zurück zu geben ... Der Buchwert von Safinamid wurde bereits im Abschluss des 4 ... Die Zusammenarbeit von Merck und Newron bei Pruvanserin und Sarizotan ist von der Entscheidung nicht betroffen. Safinamid ... Merck ... ....(size: 10.5Kb)
Edit
PR Newswire
21 Oct 2011
. GENÈVE, October 21, 2011 /PRNewswire/ --. Merck Serono, division du groupe Merck KGaA (Darmstadt, Allemagne), a annoncé aujourd'hui sa décision de restituer à Newron Pharmaceuticals S.p.A. tous les droits sur le safinamide ... La collaboration de Merck Serono avec Newron pour la pruvansérine et le sarizotan se poursuit. A propos du safinamide ... ... - L'étude 015, terminée ... A propos de Merck ... ....(size: 12.4Kb)
